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Ablation of Persistent Atrial Fibrillation
Using Multielectrode Catheters and
Duty-Cycled Radiofrequency Energy
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Nicholas S. Peters, MD,‡ Vince Paul, MD,§ Edward Rowland, MD,§ Andrew Grace, MD,
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and Ann Arbor, Michigan
Objectives The purpose of this study was to assess the efficacy and safety of a novel, multielectrode, duty-cycled radiofre-
quency ablation (RFA) system for long-standing persistent atrial fibrillation (AF).
Background RFA for persistent AF remains a lengthy and challenging procedure.
Methods In 5 European centers, 50 patients with long-standing persistent AF underwent RFA. A circular pulmonary vein
(PV) ablation catheter was used for PV isolation. Complex fractionated atrial electrograms were targeted at the
interatrial septum using a multiarray septal ablation catheter and in the left atrium using a multiarray ablation
catheter.
Results During a mean total procedure time of 155  40 min, complete PV isolation and complex fractionated atrial
electrogram ablation were achieved in all patients. In 50% of patients, redo ablation was performed using the
same strategy and technology. There were no device-related adverse events. At 6 months, a 7-day Holter electro-
cardiogram showed 80% AF reduction in 40 of 50 patients (80%), and 32 of 50 (64%) were off antiarrhythmic
drugs. At 20  4 months after the last procedure, 31 of 47 patients (66%) had a 80% reduction in AF burden,
with 21 patients (45%) free of AF and off antiarrhythmic drugs.
Conclusions This initial 50-patient multicenter study demonstrates a 80% short-term and 66% success rate at 20 months,
with a low complication rate and a relatively short procedure time in patients with persistent AF using 3 anatom-
ically specific multielectrode ablation catheters and low-energy duty-cycled radiofrequency energy. (J Am Coll
Cardiol 2009;54:1450–6) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.009e
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madiofrequency (RF) ablation (RFA) in the left atrium is an
stablished therapy for patients with persistent atrial fibril-
ation (AF) (1,2). Currently unipolar RF energy usually is
pplied at power settings of 20 to 50 W with an irrigated-tip
blation catheter. Extensive RF injury can lead to atrio-
rom the *Cardiovascular Center, Clinic im Park, Zurich, Switzerland; †St. Antonius
ospital, Nieuwegein, the Netherlands; ‡St. Mary’s Hospital, Imperial College,
ondon, United Kingdom; §St. George’s Hospital, London, United Kingdom;
Papworth Hospital, Cambridge, United Kingdom; and the ¶University of Michigan,
nn Arbor, Michigan. Dr. Scharf has served as an advisor for and received stock options
nd grant support from Ablation Frontiers. Dr. Boersma has received speakers fees and
esearch grants from and has been a consultant and stockholder for Ablation Frontiers.
r. Davies has served as a consultant for Medtronic. Dr. Kanagaratnam has been serving
n a user advisory group for, has received consulting fees from, and has held stock options
rom Ablation Frontiers. Dr. Grace has served as a consultant for and received consulting
ees from Ablation Frontiers. Dr. Fynn has held stock options from Ablation Frontiers. Dr.
ral holds equity and served as a consultant for Ablation Frontiers. Drs. Oral and Morady are
ounders of Ablation Frontiers, which was acquired by Medtronic in February 2009.s
Manuscript received April 24, 2009; revised manuscript received July 6, 2009,
ccepted July 13, 2009.sophageal fistula (3), pulmonary vein (PV) stenosis (4),
hrenic nerve paralysis (5), and gastroparesis (6). In persis-
ent AF, a modification of the left atrial substrate by linear
blation (2,7) or by ablation of complex fractionated atrial
lectrograms (CFAE) (8) is necessary. Techniques, proce-
ure duration, and strategy, as well as outcomes, are
perator-dependent (9), and post-ablation left atrial flutters
re common (7,10).
To improve efficiency, safety, and efficacy, a novel tech-
ology that delivers duty-cycled unipolar and bipolar RF
nergy at 8 to 10 W through anatomically specific multi-
lectrode catheters has been developed (11). A prior study
n patients with paroxysmal AF demonstrated a clinical
uccess rate of 83% using the PV ablation catheter
PVAC) (11). This prospective multicenter trial describes
he safety and efficacy of the PVAC and 2 other novel,
ultielectrode ablation catheters in patients with long-tanding persistent AF.
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October 6, 2009:1450–6 Duty-Cycled Radiofrequency Ablation of AFethods
tudy subjects. The study protocol was approved by the
ocal ethics committees at 5 centers in 3 European countries.
ll patients gave informed consent. Fifty patients with
ong-standing (1 year) persistent AF and with recurrence
f AF within 30 days after electrical cardioversion despite
reatment with1 Class IC or III antiarrhythmic drug therapy
rug were included (Table 1). There were a mean of 10  5
atients (range 6 to 18) per center. Patients with a prior left
trial ablation, severe structural heart disease, a left atrial
iameter 55 mm, and ejection fraction 0.40 were
xcluded. An intracardiac thrombus was ruled out by trans-
sophageal echocardiography in all patients.
echnique of duty-cycled bipolar/unipolar RFA. The
blation Frontiers Cardiac Ablation System (Ablation
rontiers, Inc., Carlsbad, California) has 3 different multi-
lectrode catheters capable of simultaneous mapping and
blation. The PVAC is a 9-F, decapolar, over-the-wire,
eflectable catheter with a 25-mm diameter spiral array at
he distal end (Fig. 1). The multiarray septal catheter
MASC) contains 6 paired electrodes on 3 arms (Fig. 2).
nce deployed into the left atrium, this catheter can ablate
FAEs by pulling back toward the septum. The multiarray
blation catheter (MAAC) has 4 arms, each with 1 pair of
lectrodes, and is used for mapping and ablation in the left
trium (Fig. 3). No other catheters were used for ablation in
hese patients.
The catheters are connected to a multichannel, duty-
ycled RF generator (GENius, Ablation Frontiers, Carls-
ad, California) capable of delivering independently pow-
red unipolar/bipolar energy to any combination of paired
lectrodes in temperature-controlled mode (Fig. 4). Unipo-
ar energy (to an external pad electrode) and bipolar energy
between adjacent, paired electrodes) is titrated up to a set
arget temperature of 60°C with maximum output of 8 to 10
in 5 pre-defined energy settings (modes): bipolar, unipo-
ar, and 3 ratios (1:1, 2:1, and 4:1) of bipolar-to-unipolar
nergy. Energy delivery was 1 min per application, and the
ode setting is selected according to desired lesion depth to
inimize the risk of collateral injury based on prior exper-
mental studies (12). For example, on the posterior wall, a
:1 ratio of bipolar-to-unipolar energy was routinely used to
void esophageal injury.
lectrophysiologic study. After femoral venous access and
ranseptal puncture, a single 10.5-F sheath was inserted into
he left atrium, and heparin was administered to maintain
n activated clotting time (ACT) 300 s. The PVs were
atients Characteristics (n  50)Table 1 Patients Characteristics (n  50)
Age (yrs) 58 7
Duration of atrial fibrillation (yrs) 3 3 (range 1–17)
Left ventricular ejection fraction 0.54 0.09
Left atrial diameter (mm) 46 5aata are shown as mean  SD.solated with the PVAC catheter
y 60-s applications of 4:1 bipo-
ar/unipolar duty-cycled RF en-
rgy. Bidirectional steering was
sed for large PV diameters or
eft common PV anatomy.
Septal ablation with the MASC
atheter and left atrial wall with
he MAAC catheter was per-
ormed using a 1:1 bipolar/
nipolar ratio or 4:1 bipolar/
nipolar ratio at the posterior wall.
he criteria and end points for
FAE ablation were left to the
perator’s discretion. However,
onversion to sinus rhythm was
ot a goal or end point of CFAE
blation. All 3 multielectrode ab-
ation catheters were used in all
atients in the first procedure and
n redo procedures.
After electrical cardioversion,
blation with the PVAC was
ontinued to eliminate all PV
otentials at the PV ostium. The
echnique and sequence of the 3
rocedure steps were similar in
edo ablations. Procedure times
ere defined as the duration of the entire procedure, from
emoral access to removal of the sheaths. Oral anticoagula-
ion was bridged with low-molecular-weight heparin, and
nfractionated heparin was used during the procedure to
aintain an ACT 300 s.
ollow-up. Oral anticoagulation was recommended for 6
onths. Follow-up visits were at 1, 2, 4, 6, and 20  4
onths after the last ablation procedure (18  4 months
range 10 to 25 months] after the last cardioversion).
uality of life was assessed at baseline and 6 months of
ollow-up with the SF-36 Quality of Life questionnaire
Quality Metrics, Lincoln, Rhode Island) and a symptom
everity score (1). Antiarrhythmic drug therapy was left to
he discretion of the investigator. Cardioversion and/or
epeat ablation was recommended for recurrent AF, prefer-
bly within the first 3 months after the procedure. One
dditional procedure using the same catheters and ablation
trategy as in the initial procedure was allowed, which reset
he 6-month end point evaluation.
Computed tomography (CT) or magnetic resonance
maging (MRI) of the heart and transthoracic echocardio-
ram were obtained at baseline and 6 months after the last
blation procedure. A 7-day continuous electrocardiogram
ECG) recording was routinely performed 6 months after
he last procedure and was interpreted at a core laboratory
y blinded investigators. Recurrence of AF was defined as
Abbreviations
and Acronyms
ACT  activated clotting
time
AF  atrial fibrillation
CFAE  complex
fractionated atrial
electrograms
CT  computed
tomography
ECG  electrocardiogram
MAAC  multiarray
ablation catheter
MASC  multiarray septal
catheter
MCS  mental component
score
MRI  magnetic resonance
imaging
PCS  physical component
score
PV  pulmonary vein
PVAC  pulmonary vein
ablation catheter
RF  radiofrequency
RFA  radiofrequency
ablationny atrial tachyarrhythmia lasting 30 s.
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Duty-Cycled Radiofrequency Ablation of AF October 6, 2009:1450–6Figure 1 PVAC
The pulmonary vein ablation catheter (PVAC) is a decapolar, circular, over-the-wire mapping and ablation catheter designed for pulmonary vein (PV) isolation. Stability is
provided by the guiding wire advanced into the pulmonary vein (PV), whereas the catheter itself is positioned at different aspects of the PV antrum for mapping and ablation.
Note the noise created by the phasing of radiofrequency (RF) energy through the ablation electrodes and the marked circumferential electrogram voltage reduction after 1 min of
RF ablation. CS  decapolar coronary sinus electrode with proximal and distal pairs.Figure 2 MASC
The multiarray septal catheter (MASC) has 3 arms with 4 electrodes each on the backside and is applied by pullback through the transseptal puncture to the left atrial
septum. The electrodes have cooling fins to prevent heating during 1:1 unipolar/bipolar duty-cycled RF delivery. Note the noise created by the phasing of RF energy
through the ablation electrodes and the marked electrogram voltage reduction after 1 min of RF ablation. Abbreviations as in Figure 1.
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October 6, 2009:1450–6 Duty-Cycled Radiofrequency Ablation of AFtudy end points. The primary efficacy end point was a
80% reduction in AF burden on the 7-day ECG record-
ng at 6 months, with or without antiarrhythmic drug
reatment. The primary safety end point consisted of
erious adverse events related to the device technology,
ncluding PV stenosis. Secondary efficacy end points were
mprovements in echocardiographic and quality-of-life
arameters.
tatistics. Continuous variables are presented as mean 
D and were compared using a paired t test or the Wilcoxon
igned-rank test for nonparametric variables. A value of p
.05 indicated statistical significance.
esults
FA. The total procedure and fluoroscopy durations were
55  40 min and 55  35 min, respectively. PV ablation
ook 32  12 min with the PVAC, followed by septal
blation with the MASC for 8  3 min and left atrial
blation for 13  5 min using the MAAC. One patient
onverted to sinus rhythm during ablation; the others
ere cardioverted. PV isolation was confirmed in all
atients.
Due to recurrent AF, 25 of 50 patients (50%) underwent
Figure 3 MAAC
The multiarray atrial ablation catheter (MAAC) has 2 electrodes on each of 4 arms
electrograms in the atrium. Cooling fins prevent overheating. Note the noise create
gram voltage reduction after 1 min of RF ablation on the chosen channels 1, 2, an
this pair of electrodes due to lack of contact. Abbreviations as in Figure 1.epeat ablation 124  50 days after the first procedure. dhree patients refused a second procedure and were counted
s single-procedure failures. During the second ablation
rocedure, a similar ablation strategy was employed. The
ean procedure time for the redo procedures was 146  53
in. Because ablation was started during AF, the extent of
V reconnection could not be quantified. Electrical cardio-
ersion was used to restore sinus rhythm in all redo
rocedures. Ablation time with each of the 3 catheters was
horter in the second than in the first procedure: 26 11 min
ersus 32  12 min for the PVAC (p  0.05), 5.4  3.5 min
ersus 8  3 min for the MASC (p  0.005), and 9.8  5.7
in versus 13  5 min for the MAAC (p  0.05).
eft atrial flutter/atrial tachycardia. Conversion to atrial
achycardia/flutter was not observed during any procedure.
uring follow-up, 2 patients developed a left atrial tachy-
ardia/flutter, with a centrifugal activation pattern at the
ower septum and right inferior PV in 1 patient and within
he left atrial appendage in the other patient. Both patients
nderwent successful ablation with a conventional
-dimensional mapping system during a third procedure,
nd both patients remained in sinus rhythm thereafter.
hese patients were counted as 6-month efficacy failures but
ere documented to have stable sinus rhythm at late
ollow-up. No macro–re-entrant left atrial flutter occurred
are designed to prevent perforation and to ablate complex fractionated atrial
he phasing of RF energy through the ablation electrodes and the marked electro-
AAC3 was not chosen for ablation, because electrograms were not present on, which
d by t
d 4. Muring follow-up.
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Duty-Cycled Radiofrequency Ablation of AF October 6, 2009:1450–6dverse events. All adverse events were recorded and
eviewed by an independent Data and Safety Monitoring
oard. There were 4 serious procedural complications: groin
ematoma in 1 patient, arteriovenous fistula requiring
urgical repair in 1 patient, cardiac tamponade from the
ransseptal puncture in 1 patient, and a prolonged reversible
schemic neurologic event manifesting as ataxia and con-
rmed by an MRI scan in 1 patient. During this procedure,
he ACT was maintained above 300 s, and no char or
hrombus was noted on the catheters. The neurologic deficit
esolved within 2 weeks. Because this event may have been
aused by an air embolus, the sheaths were routinely flushed
n all patients thereafter.
During follow-up, 1 patient developed pain and fever
ssociated with pericardial and pleural effusions at 2 months.
ymptoms resolved after a pericardial drain was placed.
ltimately the patient underwent a second ablation, and
inus rhythm was present 6 months later. A second patient
as admitted for heart failure secondary to rapidly conduct-
ng recurrent AF and was managed with rate control
edications. On follow-up CT/MRI scans, there was no
vidence of PV stenosis in any patient.
fficacy. At a mean follow up of 6.3  0.9 months after the
econd procedure, a continuous ECG was recorded for 6.7 
.8 days in all 50 patients (Table 2). Sinus rhythm was
resent in 8 of 8 patients receiving antiarrhythmic drug
herapy with amiodarone (n  5), sotalol (n  2), and
ecainide (n  1). None of the 5 patients with self-
onverting AF were receiving an antiarrhythmic drug. The
ean left ventricular ejection fraction increased from 0.55
.09 to 0.60  0.09 (p  0.005), and the mean left atrial
iameter decreased from 46  6 mm to 43  6 mm (p 
.001). Among successfully treated patients, left atrial di-
meter decreased by 4 1 mm (46 6 mm vs. 42 6 mm;
 0.001), whereas in the 10 patients with continued AF,
he left atrial diameter did not change significantly (46  8
m vs. 47  6 mm).
Long-term efficacy was assessed in 47 patients at 20  4
onths after the last ablation and 18  4 months (range 10
o 25 months) after the last cardioversion (Table 2). In the
emaining 3 patients, a 12-lead ECG at late follow-up
howed sinus rhythm in 1 patient and AF in 2 patients.
rimary Efficacy End Pointn 7-Day Continuous H lter ECGTable 2 Primary Efficacy End Pointon 7-Day Continuous Holter ECG
Primary End Point
(n  50)
Latest Follow-up
(n  47)*
Duration of follow-up (months) 6.3 0.9 20 4
AF reduction 80% 40 (80%) 31 (66%)
Free of AF 35 (70%) 28 (60%)*
Free of AF off AAD 27 (54%) 21 (45%)
AF reduction 80% off AAD 32 (64%) 22 (47%)
F recurrence was defined as any atrial tachyarrhythmia longer than 30 s on continuous 7-day ECG.
Three patients were not available for 7-day ECG beyond 12 months, 2 of them showed AF and 1
inus rhythm on a 12-lead ECG. During long-term follow-up, an additional 2 patients were in sinusw
hythm after an additional flutter ablation using 3-dimensional mapping.
AAD  antiarrhythmic drug; AF  atrial fibrillation; ECG  electrocardiogram.mprovement in symptoms. Among the 40 subjects who
aintained sinus rhythm at 6 months, the prevalence of
atigue decreased from 92% to 43%, shortness of breath
rom 78% to 29%, light-headedness from 68% to 31%, and
xercise intolerance from 92% to 41%. There were no
hanges in these symptoms among the patients with recur-
ent AF.
An SF-36 V2 Health Screening Survey (Quality Metrics,
incoln, Rhode Island) was completed at all follow-up
isits. Raw scores were calculated into component scores for
hysical (PCS) and mental (MCS) health. On a scale of 1 to
00, baseline measurements for PCS and MCS averaged
8  7 and 49  4, respectively. Patients meeting the
fficacy end point demonstrated an improvement in PCS
o 54  5 (p  0.05) and MCS to 55  6 (p  0.05),
hereas there was no significance in decreased compo-
ent scores of those with recurrent AF (PCS: 45  7 and
CS: 47  8 [p  NS]).
iscussion
his is the first study using duty-cycled RF with multielec-
rode ablation in patients with long-standing persistent AF.
he efficacy of 80% at 6 months and 66% at 20 months
ompares favorably with conventional RF (1,13), and a
rocedure time of approximately 2.5 h was relatively short.
urthermore, the incidence of post-ablation atrial flutter/
achycardia was low (4%). Preliminary results from studies
sing the same technology are similar (14,15), and a clinical
fficacy of 85% has been demonstrated in patients with
aroxysmal AF (11).
afety. Duty-cycled bipolar/unipolar RF delivery at low
nergy levels of 3 to 8 W per electrode may be helpful for
reventing complications created by extensive thermal in-
ury. Although several serious adverse events were noted in
his study, none were judged by the Data and Safety
onitoring Board to be directly related to the ablation
echnology. The lone neurological event could have resulted
rom the 10.5-F sheath, as described with standard tech-
ology (9). The absence of char with these nonirrigated
atheters may be attributable to the phasing between bipolar
nd unipolar RF, a slow ramp-up algorithm for temperature-
ontrolled ablation, and passive cooling through a unique
lectrode design.
There was no evidence of PV stenosis or atrioesophageal
stula in this study on follow-up MRI/CT scans. A prior
tudy with this technology in patients with paroxysmal AF
lso demonstrated a good safety profile (11).
fficacy. Ablation of long-standing persistent AF with a
inear approach (7,16), point-by-point ablation of CFAE
8), or extensive stepwise ablation until conversion (2,7)
emains challenging. The results have varied widely, even
mong very experienced centers (1,7,8,16).
Our results compare favorably with those of single-center
tudies (6-month success rate 80%, 20 months 66%) and
ere achieved by 8 different electrophysiologists at 5 cen-
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October 6, 2009:1450–6 Duty-Cycled Radiofrequency Ablation of AFers, suggesting that the ablation strategy is easily adoptable.
he relatively high redo rate of 50% might be explained by
he study protocol, which encouraged repeat ablation within
months. Three months may have been too short to allow
aximal lesion maturation and atrial remodeling. The
linical results translated into a significant decrease in left
trial diameter of 4 mm within the first 6 months after
blation (p  0.001). Of note is that 11% of patients who
reviously had persistent AF for 1 year had self-
onverting AF without antiarrhythmic drug treatment dur-
ng follow-up.
A long-term success rate of 66% after 20  4 months in
ong-standing persistent AF is reasonable. The 7-day con-
inuous ECG recording is comparable to that of transtele-
honic ECG transmissions as a follow-up tool (17).
uality of life. The increase in quality of life by 6 points in
uccessfully treated patients is similar to the results obtained
n studies of patients with paroxysmal AF (18,19). A
lacebo effect of ablation was not present, because nonre-
ponders did not improve. An improvement of 5 points
as been considered to be clinically meaningful (20).
tudy limitations. The main limitations of this study are
he relatively small sample size and the absence of a control
roup. A randomized study with this technology is under-
ay and will better define the efficacy of these novel
atheters in accordance with published guidelines. Although
he embolic neurologic event and the cardiac tamponade
hat occurred in this study were not considered to be directly
elated to the study devices, this possibility cannot be
xcluded, and larger studies are necessary to address safety.
The extent of PV reconnection was not quantified during
edo procedures. After conventional ablation, PV reconnec-
ion is found in the majority of patients with AF (21) or
Figure 4 Power Output and Current Density of Multipolar Elect
Technical details of multielectrodes delivering duty-cycled RF in comparison with a
rent densities are comparable because of the lower surface area of the smaller el
(MASC and MAAC). Abbreviations as in Figures 1, 2, and 3.trial tachycardia (22) and even in patients in sinus rhythm
Z23). It would be expected that a substantial proportion of
atients with recurrent AF in this study would have had
econnection. In addition, the specific sites at which CFAEs
ere ablated were not specified in this study because no
-dimensional electroanatomical mapping systems were
sed.
A possible limitation of the ablation technology used in
his study is the cost of 3 anatomically specific ablation
atheters. However, the cost for conventional AF ablation
sing a 3-dimensional mapping system includes reference
atches, a multipolar ring catheter, and an irrigated ablation
atheter. The cost of conventional ablation guided by a
-dimensional mapping system may fall into a similar range
r be less than the costs of the catheters used in this study.
onclusions
his initial 50-patient multicenter study demonstrates that
good success rate, a low complication rate, and a relatively
hort procedure time are achievable in patients with persis-
ent AF using 3 anatomically specific multielectrode abla-
ion catheters and duty-cycled RF energy. Additional stud-
es in a larger number of patients monitored for 7 to 10 days
t a time at 6, 12, 18, and 24 months of follow-up are
ecessary to validate the results of this initial study.
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